DDInter630 DDInter1147
Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family member 7, a cell surface glycoprotein. Elotuzumab consists of the complementary determining regions (CDR) of the mouse antibody, MuLuc63, grafted onto human IgG1 heavy and kappa light chain frameworks. Elotuzumab is produced in NS0 cells by recombinant DNA technology. Elotuzumab has a theoretical mass of 148.1 kDa for the intact antibody. Elotuzumab was approved on November 30, 2015 by the U.S. Food and Drug Administration. Elotuzumab
Meningococcal group C polysaccharide is group-specific polysaccharide antigens extracted and purified from *Neisseria meningitidis* serogroup C. *N. meningitidis* is a bacteria that causes endemic and epidemic diseases including meningitis and meningococcemia. It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup C.
Elotuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Paclitaxel
Elotuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Candida albicans
Elotuzumab {u} may lead to a major life threatening interaction when taken with {v} Fingolimod
Elotuzumab {u} may lead to a major life threatening interaction when taken with {v} Samarium (153Sm) lexidronam
Elotuzumab may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Elotuzumab may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Elotuzumab may lead to a major life threatening interaction when taken with Fingolimod
Elotuzumab may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam